Categories: News

TRACON to Report Fourth Quarter and Full Year 2020 Financial Results and Company Highlights on February 25, 2021

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its fourth quarter and full year 2020 financial and operating results after the close of U.S. financial markets on Thursday, February 25, 2021. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

Conference call and webcast:
Date: February 25, 2021
Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)
Dial-in: (855) 779-9066 (Domestic) or (631) 485-4859 (International)
Passcode: 5681569
Via web: www.traconpharma.com; “Events and Presentations” section within the “Investors” section

A replay of the webcast will be available for 60 days on the website.

About TRACON

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization.  In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S.  To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.

Company Contact: Investor Contact:
Mark Wiggins Brian Ritchie
Chief Business Officer LifeSci Advisors LLC
(858) 251-3492 212-915-2578
mwiggins@traconpharma.com  

Staff

Recent Posts

Health-E Commerce® expands telehealth offerings with LifeMD™ to provide sleep treatments via FSA Store® and HSA Store®

New collaboration delivers 50% off prescription sleep support for new customers who are struggling with…

4 hours ago

EnrollHere and SunFire Announce Strategic Partnership to Deliver Seamless, End-to-End Medicare Enrollment Technology

WILMINGTON, N.C. , June 9, 2025 /PRNewswire/ -- EnrollHere, a next-generation Medicare technology platform, and SunFire,…

4 hours ago

Chicago Faucets Hosts Public Health Webinar to Help Facilities Comply with Emerging Legionella Regulations

Spenser Johnson to Present "Navigating Evolving Water Management Regulations: Ensuring Compliance & Public Safety" Thursday,…

4 hours ago

Dr. Sameer Berry, Oshi Health Co-Founder and Chief Medical Officer, Named to Modern Healthcare’s 50 Most Influential Clinical Executives

In helping create and scale Oshi as the first nationwide virtual GI clinic, Berry has…

4 hours ago

Washington County, NY Sheriff’s Office First in the Nation to Provide Sheriff Rx™

Prescription Discount Program for County Employees in Partnership with BI2 Technologies, LLC FORT EDWARD, N.Y.,…

4 hours ago

Sage Adds AI-Powered Fall Detection and Wellness Trend Monitoring to its All-in-One Senior Care Platform

NEW YORK, June 9, 2025 /PRNewswire/ -- Sage, the first cloud-based operating system built for senior…

4 hours ago